



1644
Docket No. CEN-249

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants :Jill Giles-Komar et al.
Serial No. :09/920,267.
Filed :August 1, 2001.
Title :ANTI- INTEGRIN ANTIBODIES, COMPOSITIONS, METHODS AND
USES
Art Unit :1644
Examiner : Haddad, Maher M

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

November 2, 2006

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

November 2, 2006
(Date of Deposit)

Kenneth J. Dow
(Name of applicant, assignee, or Registered Representative)

/ Kenneth J. Dow /
(Signature)

November 2, 2006
(Date of Signature)

AMENDMENT

Dear Sir:

This is in response to the Office Action mailed October 16, 2006 in the above referenced application.

Please enter the following amendment:

Amendments to the Claims are reflected in the listing of claims which begin on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-3 (canceled).

Claim 4. (canceled)

Claim 5. (canceled).

Claim 6. (canceled)

Claim 7. (canceled)

Claim 8. (canceled)

Claims 9-23 (canceled)

Claim 24. (previously amended) An isolated nucleic acid encoding at least one isolated mammalian anti-dual integrin antibody comprising (i) all of the heavy chain CDR amino acid sequences of SEQ ID NOS:1, 2, and 3; and (ii) all of the light chain CDR amino acids sequences of SEQ ID NOS:4, 5, and 6.

Claim 25. (previously amended) An isolated nucleic acid vector comprising an isolated nucleic acid according to claim 24.

Claim 26. (amended) A prokaryotic or eukaryotic host cell comprising an isolated nucleic acid vector according to claim 25 [24].

Claim 27. (amended) A host cell according to claim 26, wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, P3X63Ag8.653 653,

SP2/0, 293, HeLa, myeloma, or lymphoma cells, ~~or any derivative, immortalized or transformed cell thereof.~~

Claim 28. (amended) A method for producing at least one anti-dual integrin antibody, comprising translating a nucleic acid vector according to claim 25 [24] under conditions in vitro[,] or in vivo ~~or in situ~~, such that the dual integrin antibody is expressed in detectable or recoverable amounts.

Claims 29-101. (canceled).

Claim 102 (previously presented) An isolated nucleic acid encoding a human monoclonal antibody comprising human heavy chain and human light chain variable regions comprising the amino acid sequences shown in SEQ ID NO: 7 and SEQ ID NO: 8, respectively.

Claim 103. (previously presented). An isolated nucleic acid vector comprising an isolated nucleic acid according to claim 102.

Claim 104. (amended) A prokaryotic or eukaryotic host cell comprising an isolated nucleic acid vector according to claim 103 [102].

Claim 105. (amended) A host cell according to claim 104, wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, P3X63Ag8.653 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, ~~or any derivative, immortalized or transformed cell thereof.~~

Claim 106. (amended) A method for producing at least one anti-dual integrin antibody, comprising translating a nucleic acid vector according to claim 103 [102] under conditions in vitro[,] or in vivo ~~or in situ~~, such that the dual integrin antibody is expressed in detectable or recoverable amounts.

Claim 107. (previously presented) An isolated nucleic acid according to claim 102 wherein the antibody completely inhibits M21 cell adhesion to vitronectin.

Claim 108. (previously presented) An isolated nucleic acid according to claim 102 wherein the antibody comprises a human IgG heavy chain and a human kappa light chain.

Claim 109. (previously presented) An isolated nucleic acid according to claim 102 wherein the antibody comprises an IgG1 or IgG3 heavy chain.

Claim 110 (previously presented) An isolated nucleic acid according to claim 102 wherein the antibody is an IgG1kappa antibody.

REMARKS/ARGUMENTS

Amendments have been made to address the issues presented in the Office Action. The rejection of claims 4-8, 26-28 and 104-106 under 35 USC 112, first paragraph is rendered moot by the cancellation or amendment of the claims. Claims 27 and 105 have been amended to recite the full designation for the 653 cells and to eliminate the language objected to by the Examiner. Support for the amendment can be found in the specification at page 24, line 24. Claims 24 and 104 have been amended to depend on claims 25 and 103, as suggested.

Applicant respectfully requests that a timely Notice of Allowance be issued in this case.

Respectfully submitted,

By: / Kenneth J. Dow /
Kenneth J. Dow
Reg. No. 32890

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
(610) 651-7422
Dated: November 2, 2006